• RIPA Lysis Buffer (Strong): Optimizing Protein Extraction Wo

  2026-06-11

  RIPA Lysis Buffer (Strong) empowers researchers to achieve high-yield, low-degradation protein extraction from animal tissues and cultured cells, critical for advanced immunoassays and pathway analysis. This guide details workflow enhancements, experimental troubleshooting, and practical insights inspired by recent glioma research.

• NSP2-MYB Module Coordinates Flavonoid Biosynthesis and Symbi

  2026-06-11

  Gao et al. delineate a molecular module, comprising NSP2 and MYB40, that integrates symbiotic signaling and flavonoid biosynthesis to optimize legume nodulation and mycorrhizal interactions under nutrient stress. These findings clarify how metabolic and symbiotic pathways are transcriptionally coordinated, offering new insights for plant-microbe research.

• Experimental Use of Angiotensin II: Protocols and Pitfalls

  2026-06-10

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is routinely used to model hypertension, cardiovascular remodeling, and vascular smooth muscle cell hypertrophy in both in vitro and in vivo studies. This reagent is best suited for controlled research workflows that require precise control of dosing, solubility, and storage. It is not intended for diagnostic or clinical use, and long-term solution storage or use with ethanol as a solvent should be avoided.

• Palomid 529: Applied PI3K/Akt/mTOR Inhibition in Cancer Mode

  2026-06-10

  Palomid 529 (P529) brings dual mTORC1/mTORC2 inhibition to advanced cancer and resistance studies, with potent anti-angiogenic and radiotherapy-enhancing effects. This guide delivers protocol optimizations, troubleshooting insights, and data-driven use cases for translational oncology workflows.

• RCN2 Drives ESCC Metastasis and Cisplatin Resistance via PI3

  2026-06-09

  This study uncovers the mechanism by which RCN2 promotes metastasis and cisplatin resistance in esophageal squamous cell carcinoma (ESCC). By facilitating UBR5-mediated degradation of PPP2CA, RCN2 sustains PI3K-AKT pathway activation, highlighting a new therapeutic target for aggressive, treatment-resistant ESCC.

• Elimination of Senescent Beta Cells Prevents Type 1 Diabetes

  2026-06-09

  Thompson et al. (2019) revealed that senescent pancreatic beta cells actively contribute to type 1 diabetes (T1D) pathogenesis by adopting a secretory phenotype and upregulating BCL-2, rendering them susceptible to targeted apoptosis. Their work demonstrates that selective removal of these cells via BCL-2 protein inhibitors preserves beta cell mass and prevents diabetes onset, introducing a new mechanistic understanding and therapeutic avenue for T1D.

• Light-Inducible RNA Switches for Controlled Gene Therapy

  2026-06-08

  This article analyzes a rationally designed light-inducible RNA-releasing protein (LIRP) that enables precise, optogenetic regulation of therapeutic gene expression in vivo. The work provides a significant advance in temporal and tissue-specific gene therapy control, with demonstrated applications in metabolic and retinal disease models.

• Applied Use of Tiamulin (Thiamutilin): Protocols & PK/PD Ins

  2026-06-08

  Tiamulin (Thiamutilin) stands out as a veterinary antibiotic with dual antibacterial and anti-inflammatory actions, delivering precise control over Mycoplasma gallisepticum and complex inflammatory pathways. This guide translates cutting-edge PK/PD research into actionable protocols, troubleshooting strategies, and experimental enhancements for animal models and in vitro assays.

• FAISL lncRNA Stabilizes FAK to Drive Triple Negative Breast

  2026-06-07

  The reference study uncovers lncRNA FAISL as a critical regulator of FAK protein stability in triple negative breast cancer (TNBC), revealing how FAISL blocks Calpain 2-mediated FAK proteolysis to promote tumor progression and metastasis. These mechanistic insights highlight novel therapeutic opportunities and refine biomarker strategies for aggressive TNBC subtypes.

• KU-55933: ATM Kinase Inhibitor for DNA Damage Response Assay

  2026-06-06

  KU-55933 enables precise ATM kinase inhibition for advanced DNA damage response and cancer cell cycle research. Discover experimental workflows, optimization tips, and novel protocol enhancements that set this potent and selective inhibitor apart for scientists seeking reliable, reproducible results.

• Methotrexate (SKU A4347): Reliable Outcomes in Cell Assays

  2026-06-05

  This article provides scenario-driven, evidence-based guidance on using Methotrexate (SKU A4347) to address common laboratory challenges in cell viability and immunological assays. The discussion highlights validated protocols, data-backed optimization, and vendor selection strategies for reproducible results, offering actionable insights for biomedical researchers and lab technicians.

• FH1 Small Molecule: Redefining Functional Maturation in iHep

  2026-06-05

  Explore how FH1 small molecule transforms cultured hepatocyte function and iPS cell differentiation. This in-depth analysis reveals unique insights and protocol guidance for researchers aiming to achieve advanced hepatocyte maturity.

• EZ Cap Cy5 Firefly Luciferase mRNA: Applied Dual-Reporter Wo

  2026-06-04

  EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) empowers precise, dual-mode tracking of mRNA delivery and expression in mammalian systems. Its Cap1 capping, 5-moUTP modification, and Cy5 labeling offer quantifiable gains in translational efficiency, immune evasion, and real-time visualization beyond conventional reporter mRNAs.

• Anti-Fibrotic Actions of 1-Phenyl-2-Pentanol in Hepatic Stel

  2026-06-04

  The referenced study demonstrates that 1-Phenyl-2-pentanol, derived from Moringa oleifera, suppresses hepatic stellate cell activation and key fibrotic pathways in vitro. These findings suggest 1-Phenyl-2-pentanol as a promising candidate for liver fibrosis research and establish new mechanistic links relevant to gastrointestinal physiology.

• MK-1775 (Wee1 Kinase Inhibitor): Mechanistic Depth and Assay

  2026-06-03

  Delve into the molecular mechanism and advanced assay design principles for MK-1775, a potent Wee1 kinase inhibitor. This article uniquely integrates scientific insights with practical guidance for leveraging cell cycle checkpoint abrogation in cancer research.

16704 records 1/1114 page Next 12345 下5页 Last page